Clinical Trials Browser

Hematologic Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Small Cell Lung Carcinoma

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms, Triple Negative Breast Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Breast Neoplasms

Fallopian Tube Neoplasms, Ovarian Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

Neoplasm Metastasis, Sarcoma

Breast Neoplasms, Neoplasms, Ovarian Neoplasms

Breast Neoplasms

Ovarian Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Ovarian Neoplasms

Metastatic Castration-resistant Prostate Cancer

Ovarian Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma

Breast Neoplasms, Neoplasm Metastasis

Metastatic Castration-resistant Prostate Cancer

Endometrial Neoplasms

Endometrial Neoplasms

Pathologic Complete Response, Ovarian Neoplasms

Ovarian Neoplasms

Ovarian Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

Ovarian Neoplasms

Colorectal Neoplasms

Ovarian Neoplasms

Stomach Neoplasms

Metastatic Castration-resistant Prostate Cancer

Pancreatic Neoplasms

Ovarian Neoplasms

HER2-ve Metastatic Breast Cancer

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

Ovarian Neoplasms

Ovarian Neoplasms

Ovarian Neoplasms

Ovarian Neoplasms

Clinical Trials

MK-3475-587

MK 7339-013

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

MK-7339-012

OlympiA

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

KEYLYNK-001

OVATION-3

MULTISARC

ROSY-O

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

PLANET

Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)

MONO-OLA1

Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)

KEYLYNK-008

OlympiAD

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

RAINBO-RED

DUO-E

SOLO-1

Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

L-MOCA

KEYLYNK-010

DUO-O

LYNK-003

OPINION

Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer.

Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)

POLO

MITO 35B

To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.

OReO

ICON9

PAOLA-1

SOLO3

Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations